What have we signed up to? A comparative analysis of the EU deals with BigPharma
15 JUL 2021 . 1PM CET
Since the beginning of the pandemic, governments have spent at least €93 billion on COVID-19 vaccines and therapeutics globally. This money went into the coffers of pharmaceutical companies. But, which interests were defended? Those of profit, or those of public health?
To better answer this question, The Left commissioned a study to analyze the different agreements that pharmaceutical companies signed with the European Commission and other institutions.
The study carried out by Medicine Law & Policy, a research group working in the public interest, analyses five contracts: Eu-AstraZeneca, Eu-CureVac, Eu-Moderna, Uk-AstraZeneca, and Us-Moderna. Although most of the documents are heavily redacted, the comparative analysis allows drawing important conclusions and it shows that the European Commission was not able – unlike other institutions – to secure advantageous clauses.
To find out more, The Left is happy to invite you to the launch event of the study. Thursday the 15th of July (13.00 – 14.30) MEPs Silvia Modig and Katerina Konecna will be joined by Ellen t’Hoen LLM Phd (ML&P, author of the study), Olivier Hoedeman (CEO), Yannis Natsis (EPHA) to present and comment on the findings of the study.
The event will be in English, with French and Spanish interpretation.
To register for the online event click here
Thursday, 15th of July 2021, 13.00 – 14.30 on Zoom
Welcome and opening remarks, Silvia Modig MEP, ENVI Coordinator for the Left
Presentation of the study by the author, Ellen t’Hoen LLM PHD, Researcher, MLP
Intervention, Olivier Hoedeman, Research and Campaign coordinator, CEO
Intervention, Yannis Natsis, Policy manager, EPHA
Discussion with participants
Conclusions, Kateřina Konečná MEP, The Left group health expert